
Keywords: VMAT2; Norepinephrine; Parkinson's disease; Locus ceruleusDA, dopamine; DHPG, 3,4-dihydroxyphenylglycol; DOPAC, 3,4-dihydroxyphenylacetic acid; DOPAL, 3,4-dihydroxyphenylacetaldehyde; DOPEGAL, 3-4-dihydroxyphenylglycolaldehyde; LC, locus ceruleus; MAO, mo